Drugs / GLA-LSQ
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04177355 | Jan 2020 → Nov 2024 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02647489 Background | May 2016 → Nov 2017 | malaria | University Hospital Tuebingen | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLA-LSQ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04177355 ↗ |
| Action | Activate | “GLA-SE and GLA-LSQ, synthetic TLR-4 agonists with a strong immune stimulatory effect” NCT02647489 ↗ |
| Modality | Other / unclassified | “GLA-SE and GLA-LSQ, synthetic TLR-4 agonists with a strong immune stimulatory effect” NCT02647489 ↗ |